Caribou Biosciences Receives FDA RMAT Designation for CAR-T Therapy

Caribou Biosciences has seen its stock rise following the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its CAR-T cell therapy, indicating accelerated development and review for the innovative treatment.